These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1792441)

  • 41. Use of statins and fibrates in hyperlipidemic patients with neuromuscular disorders.
    Leung NM; Ooi TC; McQueen MJ
    Ann Intern Med; 2000 Mar; 132(5):418-9. PubMed ID: 10691600
    [No Abstract]   [Full Text] [Related]  

  • 42. Effect of the peroxisome proliferators ciprofibrate and perfluorodecanoic acid on eicosanoid concentrations in rat liver.
    Wilson MW; Leung LK; Hong JT; Glauert HP
    Adv Exp Med Biol; 1997; 400A():439-45. PubMed ID: 9547588
    [No Abstract]   [Full Text] [Related]  

  • 43. Species differences in the hepatic response to a potent peroxisome proliferator.
    Makowska JM; Bonner FW; Goldfarb PS; Gibson GG
    Biochem Soc Trans; 1989 Dec; 17(6):1072-3. PubMed ID: 2628085
    [No Abstract]   [Full Text] [Related]  

  • 44. Role of eicosanoid metabolism in carcinogenesis by peroxisome proliferators.
    Glauert HP; Hong JT; Leung LK; Wilson MW
    Ann N Y Acad Sci; 1996 Dec; 804():719-21. PubMed ID: 8993604
    [No Abstract]   [Full Text] [Related]  

  • 45. [The treatment of chronic ischemic heart disease: the potentials for hypolipidemic correction using current drugs].
    Tashchuk VK; Makoviĭchuk IO; Bilets'kyĭ SV; Hrechko SI; Polishchuk OIu; Turubarova NA
    Lik Sprava; 1998; (5):101-3. PubMed ID: 9793321
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rhabdomyolysis and lipid-lowering drugs.
    Tenenbaum A; Fisman EZ; Motro M
    JAMA; 2005 Mar; 293(12):1448; author reply 1448-9. PubMed ID: 15784863
    [No Abstract]   [Full Text] [Related]  

  • 47. Effect of ciprofibrate on C-reactive protein and fibrinogen levels.
    Rizos E; Kostoula A; Elisaf M; Mikhailidis DP
    Angiology; 2002; 53(3):273-7. PubMed ID: 12025914
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.
    Zimetbaum P; Frishman WH; Kahn S
    J Clin Pharmacol; 1991 Jan; 31(1):25-37. PubMed ID: 2045526
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Ciprofibrate: erythrocyte partition coefficient and binding to serum protein].
    Czejka M
    Arch Pharm (Weinheim); 1991 May; 324(5):287-9. PubMed ID: 1888266
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ciprofibrate versus gemfibrozil in the treatment of primary hyperlipidaemia.
    Knipscheer HC; de Valois JC; van den Ende B; Wouter ten Cate J; Kastelein JJ
    Atherosclerosis; 1996 Jul; 124 Suppl():S75-81. PubMed ID: 8831919
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The enantiomeric resolution of ciprofibrate and related compounds by HPLC using chiral stationary phases.
    Anderson NH; Johnston D; Vojvodic PR
    J Pharm Biomed Anal; 1992 Jul; 10(7):501-5. PubMed ID: 1420475
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of ciprofibrate on gastric secretion in the rat.
    Eason CT; Pattison A; Howells DD; Bonner FW
    J Pharm Pharmacol; 1988 Jul; 40(7):512-3. PubMed ID: 2904995
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Single and chronic administration of ciprofibrate or of ciprofibrate-glycinate in male Fischer 344 rats: comparison of the effects on morphological and biochemical parameters in liver and blood.
    Lupp A; Karge E; Danz M; Deufel T; Oelschläger H; Klinger W
    Eur J Drug Metab Pharmacokinet; 2005; 30(3):203-18. PubMed ID: 16250258
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Statin-fibrate combinations in patients with combined hyperlipedemia.
    Athyros VG; Papageorgiou AA; Kontopoulos AG
    Atherosclerosis; 2001 Mar; 155(1):263-4. PubMed ID: 11293392
    [No Abstract]   [Full Text] [Related]  

  • 55. Therapeutic effects of fibrates in postprandial lipemia.
    Kolovou GD; Kostakou PM; Anagnostopoulou KK; Cokkinos DV
    Am J Cardiovasc Drugs; 2008; 8(4):243-55. PubMed ID: 18690758
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Antilipemic therapy in dyslipidemias in obese non-insulin-dependent diabetics (ONIDDM)].
    Palel G; Coman A; Petrovanu R; Ungureanu D; Cojocaru M
    Rev Med Chir Soc Med Nat Iasi; 1997; 101(3-4):120-2. PubMed ID: 10756782
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Synthesis and physico-chemical characterisation of some new derivatives of rutoside and clofibric acid].
    Lupaşcu D; Profire L; Dănilă G
    Rev Med Chir Soc Med Nat Iasi; 2006; 110(1):224-7. PubMed ID: 19292111
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mode of action of fibrates.
    Catapano AL
    Pharmacol Res; 1992 Dec; 26(4):331-40. PubMed ID: 1294939
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Fibrate-induced increase in serum creatinine levels: two cases].
    Décaudin B; Beraud G; Lannoy D; Semjen E; Wierre L; Horrent S; Résibois JP; Azar R; Odou P
    Therapie; 2005; 60(6):601-2. PubMed ID: 16555504
    [No Abstract]   [Full Text] [Related]  

  • 60. [Drug-induced myopathies].
    Ando H; Fujimura A
    Nihon Rinsho; 2007 Oct; 65 Suppl 8():390-3. PubMed ID: 18074569
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.